EFFECTIVENESS AND TOLERABILITY OF LOW-DOSE CYCLOPHOSPHAMIDE AND LOW-DOSE INTRAVENOUS INTERLEUKIN-2 DISSEMINATED MELANOMA

被引：216
|
作者：
MITCHELL, MS
KEMPF, RA
HAREL, W
SHAU, H
BOSWELL, WD
LIND, S
BRADLEY, EC
机构：
[1] UNIV SO CALIF,SCH MED,DEPT MED,LOS ANGELES,CA 90033
[2] UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033
[3] UNIV SO CALIF,SCH MED,DEPT RADIOL,LOS ANGELES,CA 90033
[4] CETUS CORP,EMERYVILLE,CA 94608
来源：
JOURNAL OF CLINICAL ONCOLOGY | 1988年 / 6卷 / 03期
关键词：
D O I：
10.1200/JCO.1988.6.3.409
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：409 / 424
页数：16
相关论文
共 50 条
  • [21] A MULTICENTER TRIAL OF INTERLEUKIN-2 AND LOW-DOSE CYCLOPHOSPHAMIDE IN HIGHLY CHEMOTHERAPY-RESISTANT MALIGNANCIES
    LINDEMANN, A
    HOEFFKEN, K
    SCHMIDT, RE
    DIEHL, V
    KLOKE, O
    GAMM, H
    HAYUNGS, J
    OSTER, W
    BOEHM, M
    FRANKS, CR
    HERRMANN, F
    MERTELSMANN, R
    CANCER TREATMENT REVIEWS, 1989, 16 : 53 - 57
  • [22] High-dose interleukin-2 may not be superior to low-dose interleukin-2 plus interferon - Reply
    McDermott, DF
    Regan, MM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 6268 - 6269
  • [23] IMMUNOLOGICAL EFFECTS OF THERAPY WITH LOW-DOSE CYCLOPHOSPHAMIDE (CY) AND RECOMBINANT INTERLEUKIN-2 (IL2)
    HAREL, W
    SHAU, H
    HADLEY, C
    STAHLBERG, J
    REISFELD, R
    CHERESH, D
    MITCHELL, M
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 401 - 401
  • [24] Low-dose intravenous bolus interleukin-2 with interferon-alpha therapy for metastatic melanoma and renal cell carcinoma
    Karp, SE
    JOURNAL OF IMMUNOTHERAPY, 1998, 21 (01): : 56 - 61
  • [25] LOW-DOSE INTRAVENOUS HEPARIN IN TREATMENT OF DISSEMINATED INTRAVASCULAR COAGULATION
    GUREWICH, V
    LIPINSKI, B
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1977, 274 (01): : 83 - 86
  • [26] The effectiveness of low-dose intravenous immunoglobulin in chronic urticaria
    Kroiss, M
    Vogt, T
    Landthaler, M
    Stolz, W
    ACTA DERMATO-VENEREOLOGICA, 2000, 80 (03) : 225 - 225
  • [27] Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccine
    Woodson, EMH
    Chianese-Bullock, KA
    Wiernasz, CJ
    Bissonette, EA
    Grosh, WW
    Neese, PY
    Merrill, PK
    Barnd, DL
    Petroni, GR
    Slingluff, CL
    JOURNAL OF IMMUNOTHERAPY, 2004, 27 (05) : 380 - 388
  • [28] Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma
    Masucci, Giuseppe Valentino
    Mansson-Brahme, Eva
    Ragnarsson-Olding, Boel
    Nilsson, Bo
    Wagenius, Gunnar
    Hansson, Johan
    MELANOMA RESEARCH, 2006, 16 (04) : 357 - 363
  • [29] Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2
    D Przepiorka
    KA Jaeckle
    RR Birdwell
    GN Fuller
    AJ Kumar
    YO Huh
    I McCutcheon
    Bone Marrow Transplantation, 1997, 20 : 983 - 987
  • [30] LOW-DOSE REGIMEN OF INTERLEUKIN-2 FOR METASTATIC RENAL-CARCINOMA
    SLEIJFER, DT
    JANSSEN, RAJ
    WILLEMSE, PHB
    MARTENS, A
    DELEIJ, L
    DEVRIES, EGE
    MULDER, NH
    LANCET, 1990, 335 (8704): : 1522 - 1523
12345